YES, a novel therapeutic target in hepatocellular carcinoma

Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapouge, Marjorie, Meloche, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067521/
https://www.ncbi.nlm.nih.gov/pubmed/35529900
http://dx.doi.org/10.1080/23723556.2022.2069993
_version_ 1784700023306452992
author Lapouge, Marjorie
Meloche, Sylvain
author_facet Lapouge, Marjorie
Meloche, Sylvain
author_sort Lapouge, Marjorie
collection PubMed
description Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies the tyrosine kinase YES as a potential therapeutic target in HCC.
format Online
Article
Text
id pubmed-9067521
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-90675212022-05-05 YES, a novel therapeutic target in hepatocellular carcinoma Lapouge, Marjorie Meloche, Sylvain Mol Cell Oncol Author’s Views Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies the tyrosine kinase YES as a potential therapeutic target in HCC. Taylor & Francis 2022-05-01 /pmc/articles/PMC9067521/ /pubmed/35529900 http://dx.doi.org/10.1080/23723556.2022.2069993 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s Views
Lapouge, Marjorie
Meloche, Sylvain
YES, a novel therapeutic target in hepatocellular carcinoma
title YES, a novel therapeutic target in hepatocellular carcinoma
title_full YES, a novel therapeutic target in hepatocellular carcinoma
title_fullStr YES, a novel therapeutic target in hepatocellular carcinoma
title_full_unstemmed YES, a novel therapeutic target in hepatocellular carcinoma
title_short YES, a novel therapeutic target in hepatocellular carcinoma
title_sort yes, a novel therapeutic target in hepatocellular carcinoma
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067521/
https://www.ncbi.nlm.nih.gov/pubmed/35529900
http://dx.doi.org/10.1080/23723556.2022.2069993
work_keys_str_mv AT lapougemarjorie yesanoveltherapeutictargetinhepatocellularcarcinoma
AT melochesylvain yesanoveltherapeutictargetinhepatocellularcarcinoma

Ejemplares similares